Standard

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{cce58bf275a24955815d37238d42e192,
title = "Active pharmaceutical ingredient (API) production involving continuous processes – A process system engineering (PSE)-assisted design framework",
keywords = "Design framework, Methodology, Continuous pharmaceutical manufacturing, Continuous processes, Microfluidic, Active pharmaceutical ingredient",
publisher = "Elsevier BV",
author = "{Cervera Padrell}, {Albert Emili} and Tommy Skovby and Søren Kiil and Rafiqul Gani and Krist Gernaey and Philip Lutze",
year = "2012",
doi = "10.1016/j.ejpb.2012.07.001",
volume = "82",
number = "2",
pages = "437--456",
journal = "European Journal of Pharmaceutics and Biopharmaceutics",
issn = "0939-6411",

}

RIS

TY - JOUR

T1 - Active pharmaceutical ingredient (API) production involving continuous processes – A process system engineering (PSE)-assisted design framework

A1 - Cervera Padrell,Albert Emili

A1 - Skovby,Tommy

A1 - Kiil,Søren

A1 - Gani,Rafiqul

A1 - Gernaey,Krist

A1 - Lutze,Philip

AU - Cervera Padrell,Albert Emili

AU - Skovby,Tommy

AU - Kiil,Søren

AU - Gani,Rafiqul

AU - Gernaey,Krist

AU - Lutze,Philip

PB - Elsevier BV

PY - 2012

Y1 - 2012

N2 - A systematic framework is proposed for the design of continuous pharmaceutical manufacturing processes. Specifically, the design framework focuses on organic chemistry based, active pharmaceutical ingredient (API) synthetic processes, but could potentially be extended to biocatalytic and fermentation-based products. The method exploits the synergic combination of continuous flow technologies (e.g., microfluidic techniques) and process systems engineering (PSE) methods and tools for faster process design and increased process understanding throughout the whole drug product and process development cycle. The design framework structures the many different and challenging design problems (e.g., solvent selection, reactor design, and design of separation and purification operations), driving the user from the initial drug discovery steps – where process knowledge is very limited – toward the detailed design and analysis. Examples from the literature of PSE methods and tools applied to pharmaceutical process design and novel pharmaceutical production technologies are provided along the text, assisting in the accumulation and interpretation of process knowledge. Different criteria are suggested for the selection of batch and continuous processes so that the whole design results in low capital and operational costs as well as low environmental footprint. The design framework has been applied to the retrofit of an existing batch-wise process used by H. Lundbeck A/S to produce an API: zuclopenthixol. Some of its batch operations were successfully converted into continuous mode, obtaining higher yields that allowed a significant simplification of the whole process. The material and environmental footprint of the process – evaluated through the process mass intensity index, that is, kg of material used per kg of product – was reduced to half of its initial value, with potential for further reduction. The case-study includes reaction steps typically used by the pharmaceutical industry featuring different characteristic reaction times, as well as L–L separation and distillation-based solvent exchange steps, and thus constitutes a good example of how the design framework can be useful to efficiently design novel or already existing API manufacturing processes taking advantage of continuous processes.

AB - A systematic framework is proposed for the design of continuous pharmaceutical manufacturing processes. Specifically, the design framework focuses on organic chemistry based, active pharmaceutical ingredient (API) synthetic processes, but could potentially be extended to biocatalytic and fermentation-based products. The method exploits the synergic combination of continuous flow technologies (e.g., microfluidic techniques) and process systems engineering (PSE) methods and tools for faster process design and increased process understanding throughout the whole drug product and process development cycle. The design framework structures the many different and challenging design problems (e.g., solvent selection, reactor design, and design of separation and purification operations), driving the user from the initial drug discovery steps – where process knowledge is very limited – toward the detailed design and analysis. Examples from the literature of PSE methods and tools applied to pharmaceutical process design and novel pharmaceutical production technologies are provided along the text, assisting in the accumulation and interpretation of process knowledge. Different criteria are suggested for the selection of batch and continuous processes so that the whole design results in low capital and operational costs as well as low environmental footprint. The design framework has been applied to the retrofit of an existing batch-wise process used by H. Lundbeck A/S to produce an API: zuclopenthixol. Some of its batch operations were successfully converted into continuous mode, obtaining higher yields that allowed a significant simplification of the whole process. The material and environmental footprint of the process – evaluated through the process mass intensity index, that is, kg of material used per kg of product – was reduced to half of its initial value, with potential for further reduction. The case-study includes reaction steps typically used by the pharmaceutical industry featuring different characteristic reaction times, as well as L–L separation and distillation-based solvent exchange steps, and thus constitutes a good example of how the design framework can be useful to efficiently design novel or already existing API manufacturing processes taking advantage of continuous processes.

KW - Design framework

KW - Methodology

KW - Continuous pharmaceutical manufacturing

KW - Continuous processes

KW - Microfluidic

KW - Active pharmaceutical ingredient

U2 - 10.1016/j.ejpb.2012.07.001

DO - 10.1016/j.ejpb.2012.07.001

JO - European Journal of Pharmaceutics and Biopharmaceutics

JF - European Journal of Pharmaceutics and Biopharmaceutics

SN - 0939-6411

IS - 2

VL - 82

SP - 437

EP - 456

ER -